Skip to main content
RENALYTIX PLC logo

RENALYTIX PLC — Investor Relations & Filings

Ticker · RENX ISIN · GB00BYWL4Y04 LEI · 213800NTOH3FK3WER551 IL Human health and social work activities
Open in API
Filings indexed 444 across all filing types
Latest filing 2024-10-08 Declaration of Voting R…
Country GB United Kingdom
Listing IL RENX

About RENALYTIX PLC

https://renalytix.com/

Renalytix is a diagnostics company that develops artificial intelligence-enabled solutions for the clinical management of kidney disease. Its flagship product, KidneyIntelX.dkd™, is an FDA-authorized blood test for adults with type 2 diabetes and early-stage chronic kidney disease. The test utilizes a proprietary bioprognostic™ methodology to analyze biomarkers and clinical data, predicting the risk of a progressive decline in kidney function over a five-year period. This risk assessment enables clinicians to identify high-risk patients and implement targeted, guideline-recommended treatments to slow disease progression and improve outcomes.

Recent filings

Filing Released Lang Actions
Admission of Shares & Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content discusses the admission of new ordinary shares, changes in total voting rights, and future share issuances contingent on a General Meeting. This is a regulatory announcement concerning share capital changes and voting rights. While it touches upon capital structure (CAP) and voting rights (DVA), the primary nature of this specific announcement, which details the mechanics of share issuance and the resulting total voting rights denominator for FCA disclosure rules, fits best under a general regulatory announcement category. Given the specific content about share issuance and voting rights calculation, 'SHA' (Share Issue/Capital Change) is highly relevant, but since it is distributed via RNS and deals with the total voting rights denominator, 'RNS' (General Regulatory Filings) is a strong candidate if SHA is too narrow. However, the core subject is the admission of new shares and the resulting total voting rights, which directly relates to capital structure changes and shareholder notification requirements. Since the document explicitly details the number of shares being admitted and the resulting total voting rights, 'SHA' (Share Issue/Capital Change) is the most precise fit for the primary corporate action described, even though it is distributed via RNS. Given the options, 'SHA' captures the substance better than the general 'RNS' fallback, although 'DVA' is also related via the voting rights denominator. I will select SHA as the primary action is a share issue.
2024-10-08 English
Commencement of trading on OTCQB in the US
Delisting Announcement Classification · 99% confidence The document is an official announcement released via RNS (RNS Number: 3346H) on October 8, 2024. The core content announces that Renalytix plc's American Depository Shares (ADSs) have commenced trading on the OTCQB Venture Market under the symbol 'RNLXY', effective from the market open on October 8, 2024. This action involved filing Form 25 with the SEC and ceasing trading on Nasdaq. This type of announcement relates to a change in the company's listing status and market structure, which is a significant corporate event. While it involves regulatory filings (Form 25), the primary purpose is to inform the market of a listing change. This fits best under 'Regulatory Filings' (RNS) as a general corporate announcement disseminated through the official news service, or potentially 'Capital/Financing Update' (CAP) due to the context of cost reduction and strategic focus, but RNS is the most accurate fit for a general, time-sensitive regulatory news service release that isn't a standard financial report or insider trade. Given the options, RNS serves as the best general category for this type of market update disseminated via the LSE's news service.
2024-10-08 English
Result of Placing and Subscription
Capital/Financing Update Classification · 98% confidence The document is an official announcement released via RNS (RNS Number: 4887G) on October 1, 2024. The content explicitly details the 'Result of Placing and Subscription,' confirming the gross proceeds raised (£11.8 million) through the issuance of new Ordinary Shares at a specific price (9 pence). It discusses related party transactions involving directors and substantial shareholders, outlines conditions for admission to trading (First Admission and Second Admission), and provides a timetable for a future General Meeting to approve resolutions necessary for the full issuance of shares. This content directly relates to fundraising, capital structure changes, and the issuance of new securities, fitting the definition of a Capital/Financing Update (CAP). While it is an RNS filing, the specific nature of the content (fundraising results) makes CAP a more precise classification than the general fallback RNS.
2024-10-01 English
Audited US GAAP financial results
Report Publication Announcement Classification · 99% confidence The document explicitly states it confirms the publication of 'Audited US GAAP financial results for the fiscal year ended 30 June 2024 as disclosed in its Form 10-K filed with the Securities and Exchange Commission.' Furthermore, the text includes detailed tables titled 'CONSOLIDATED BALANCE SHEETS' and 'CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS' for the year ended June 30, 2024. This content is characteristic of a full Annual Report (10-K). Although it is an announcement confirming the filing, the inclusion of the full financial statements (Balance Sheet and Income Statement) makes the primary classification the report itself, which aligns with the 10-K definition, rather than just an RPA.
2024-10-01 English
Placing and Subscription
Share Issue/Capital Change Classification · 99% confidence The document is a formal announcement from Renalytix PLC, identified by the RNS Number (3313G) and the use of the 'National Storage Mechanism' header, indicating a regulatory filing in the UK. The content explicitly details a 'Placing and Subscription' to raise a minimum of £10 million, the proposed conversion of existing debt into equity, and an intention to transfer its US listing from Nasdaq to OTCQX. These actions—raising capital through share issuance (Placing/Subscription) and restructuring debt into equity—are core components of a financing activity announcement. This aligns directly with the definition of 'Capital/Financing Update' (CAP). Although it is a regulatory filing (RNS), the specific subject matter is financing, making CAP the most precise classification. The document is comprehensive and appears to be the full announcement, not just a notice of publication.
2024-09-30 English
Re. Results for the fiscal year ended 30 June '24
Report Publication Announcement Classification · 99% confidence The document is an RNS announcement (indicated by 'RNS Number : 3303G' and the footer referencing RNS/LSE) from Renalytix plc. The core purpose of this announcement is to state that the company "will announce later today its audited US GAAP financial results for the fiscal year ended 30 June 2024 as disclosed in its Form 10-K filed with the Securities and Exchange Commission." It also provides preliminary IFRS results. Since the document itself is an announcement *about* the release of financial results (specifically mentioning the 10-K filing and providing preliminary data), and it is distributed via RNS, it fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given that it explicitly announces the publication of the 10-K results and provides a link, RPA is the most precise fit, as it signals the release of a major report. However, since it also contains preliminary financial data and is a formal regulatory notification, RNS (the general regulatory fallback) is also highly applicable. Comparing RPA (Report Publication Announcement) and ER (Earnings Release), this is not the primary Earnings Release (ER) which usually contains the full highlights; rather, it's an announcement regarding the filing of the 10-K and the release of preliminary IFRS data. Given the structure and the explicit mention of the 10-K filing, RPA is the best fit for announcing the availability/release of the official reports.
2024-09-30 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.